Ignite Creation Date:
2024-05-06 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04686045
Status:
UNKNOWN
Last Update Posted:
2021-01-26
First Post:
2020-12-22
Brief Title:
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020
Sponsor:
Jan Kochanowski University
Organization:
Jan Kochanowski University
Study Overview
Official Title:
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation AF European and American guidelines recommend the use of non-vitamin K antagonist oral anticoagulants NOACs over therapy with vitamin K antagonists VKA in most AF patients The number of patients treated with NOACs has increased significantly during the last few years In the primary randomized controlled trials leading to their approval compared to warfarin NOACs were shown to be either noninferior or superior for stroke prevention in AF with similar or reduced rates of bleeding especially intracranial haemorrhage
The aim of this study was to assess the frequency of oral anticoagulants using espescially apixaban dabigatran and rivaroxaban and the predictors of their prescription in a group of hospitalised patients with AF
The aim of this study was to assess the frequency of oral anticoagulants using espescially apixaban dabigatran and rivaroxaban and the predictors of their prescription in a group of hospitalised patients with AF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None